3rd Quarter - Report

PRIME THERAPEUTICS for PRIME THERAPEUTICS

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

116th Congress S. 1895, The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs; 116th Congress H.R. 19-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing; 116th Congress H.R. 3-Elijah E. Cummings Lower Drug Costs Act Now,--provisions establishing drug pricing and Part D cost sharing; Value-based contracting for pharmaceuticals; 116th Congress H.R. 5304, PBM Transparency in Prescription Drug Costs Act,--provisions related to PBM contracting; education on the value of biosimilars; outreach on PBMs role in social determinants of health and education and outreach on drug patent thickets and other pharmaceutical anticompetitive behavior; S.Con.Res.14 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031 provisions related to drug pricing and a change to the safe harbor rules for drug rebates.

LobbyistCovered position, as disclosed
JULIE CAROL CANTOR-WEINBERG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 19 (117th), H.R. 3 (117th), S.Con.Res. 14 (117th), H.R. 5304 (117th), S. 1895 (117th)

Medicare/Medicaid MMM

Implementation of S. 2003 of the SUPPORT Act of Patients and Communities Act,--provisions related to the implementation of Every Prescription Conveyed Securely Act, Final Rule, Department of Health and Human Services: Office of Inspector General, issued November 20, 2020 entitled Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Services Fees,; outreach on pharmacy direct and indirect remuneration in Medicare Part D; H.R. 19/S. 2164-Lower Cost, More Cures Act, provisions on drug prices and Part D cost-sharing and Part D reform; H.R. 3-Elijah E. Cummings Lower Drug Costs Act Now, --Provisions establishing drug pricing and Part D cost sharing; value-based contracting for pharmaceuticals; 116th Congress S. 4199, Prescription Drug Pricing Reduction Act of 2020,--provisions related to PBMs, Part D cost-sharing, inflation rebates and drug pricing; H.R. 2846, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021-formulary tiering of biosimilars and generics in Medicare Part D; . H.R.5237 -"To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes--provisions related to drug price negotiation, PBM audits, pharmacy disclosures and payments and drug rebates; S. 2327, Seniors Prescription Drug Relief Act, provisions allowing Medicare beneficiaries to spread their cost-sharing across a plan year; H.R. 3684, Infrastructure Investment Act,--provisions related to the repeal of a rule repealing the safe harbor for drug rebate; S.Con.Res.14 - A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031 provisions related to drug pricing and a change to the safe harbor rules for drug rebates.

LobbyistCovered position, as disclosed
JULIE CAROL CANTOR-WEINBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 2327 (117th), H.R. 3 (117th), H.R. 5237 (117th), H.R. 3684 (117th), S. 2164 (117th), S.Con.Res. 14 (117th), S. 2003 (117th), S. 4199 (117th), H.R. 2846 (117th), H.R. 19 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.